LBT-SA7 / LimmaTech Biologics, Eli Lilly - LARVOL DELTA

Dismantling S. aureus Virulence: Latest Advances in Toxin Neutralization and Regulatory Network-Targeted Anti-Virulence Strategies (2025). (PubMed, Microb Pathog) - "Key strategies include toxin-neutralizing monoclonal antibodies (suvratoxumab, tosatoxumab, and the discontinued ASN100 combination), SaeR inhibitors (e.g., HR3744, SAV13), RNAIII-blocking peptides, nanoparticle-based "decoy" systems, natural compounds modulating quorum sensing and toxin expression, and multivalent toxoid vaccines (notably LBT-SA7, which received FDA Fast Track designation in late 2024 and initiated Phase 1 trials in 2025 for prevention of skin and soft tissue infections). Major translational hurdles persist, including virulence factor redundancy, extensive strain heterogeneity, suboptimal pharmacokinetics, and potential for compensatory adaptations. Nevertheless, synergistic combinations with conventional antibiotics and precision-guided, multi-target regimens informed by individual virulence profiling hold substantial promise for improving outcomes in chronic, resistant, and biofilm-associated S. aureus infections."

Journal • Review • Infectious Disease

LimmaTech Vaccinates First Participants in Phase 1 Study of Staphylococcus aureus Vaccine Candidate LBT-SA7 (Businesswire) - "LimmaTech Biologics AG...announced today that the first participants have been vaccinated in a Phase 1 controlled study of its multivalent vaccine candidate, LBT-SA7. The candidate is designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen Staphylococcus aureus (S. aureus). In this context, the company also announced the award of US$6.5 million from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance the clinical development of LBT-SA7....Initial results are anticipated in the second half of 2025."

Financing • P1 data • Trial status • Infectious Disease